SG11201501653RA - Methods for the treatment of locally advanced breast cancer - Google Patents
Methods for the treatment of locally advanced breast cancerInfo
- Publication number
- SG11201501653RA SG11201501653RA SG11201501653RA SG11201501653RA SG11201501653RA SG 11201501653R A SG11201501653R A SG 11201501653RA SG 11201501653R A SG11201501653R A SG 11201501653RA SG 11201501653R A SG11201501653R A SG 11201501653RA SG 11201501653R A SG11201501653R A SG 11201501653RA
- Authority
- SG
- Singapore
- Prior art keywords
- treatment
- methods
- breast cancer
- locally advanced
- advanced breast
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4703—Regulators; Modulating activity
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hospice & Palliative Care (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261699170P | 2012-09-10 | 2012-09-10 | |
| PCT/US2013/058744 WO2014039960A1 (en) | 2012-09-10 | 2013-09-09 | Methods for the treatment of locally advanced breast cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201501653RA true SG11201501653RA (en) | 2015-04-29 |
Family
ID=49170950
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201501653RA SG11201501653RA (en) | 2012-09-10 | 2013-09-09 | Methods for the treatment of locally advanced breast cancer |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US9694015B2 (en) |
| EP (1) | EP2892537A1 (en) |
| JP (1) | JP6306592B2 (en) |
| KR (1) | KR20150054962A (en) |
| CN (1) | CN104797256A (en) |
| AU (1) | AU2013312188A1 (en) |
| BR (1) | BR112015005243A2 (en) |
| CA (1) | CA2884103A1 (en) |
| EA (1) | EA201590535A1 (en) |
| IL (1) | IL237558A0 (en) |
| MX (1) | MX2015003114A (en) |
| NI (1) | NI201500032A (en) |
| PH (1) | PH12015500513A1 (en) |
| SG (1) | SG11201501653RA (en) |
| WO (1) | WO2014039960A1 (en) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE035389T2 (en) | 2006-09-26 | 2018-05-02 | Celgene Corp | 5-substituted quinazolinone derivatives as anti-cancer agents |
| RU2567753C2 (en) | 2010-02-11 | 2015-11-10 | Селджин Корпорейшн | Arylmethoxy isoindolin derivative, compositions including thereof and methods of their application |
| NO2683708T3 (en) | 2011-03-11 | 2018-03-31 | ||
| US9090585B2 (en) | 2011-03-28 | 2015-07-28 | Deuterx, Llc | 2,6-dioxo-3-deutero-piperdin-3-yl-isoindoline compounds |
| US8604016B2 (en) | 2011-11-21 | 2013-12-10 | Calithera Biosciences Inc. | Heterocyclic inhibitors of glutaminase |
| US9682952B2 (en) | 2012-09-04 | 2017-06-20 | Celgene Corporation | Isotopologues of 3-(5-amino-2-methyl-4-oxoquinazolin-3(4H)-yl) piperidine-2-6-dione and methods of preparation thereof |
| US9540340B2 (en) | 2013-01-14 | 2017-01-10 | Deuterx, Llc | 3-(5-substituted-4-oxoquinazolin-3(4H)-yl)-3-deutero-piperidine-2,6-dione derivatives and compositions comprising and methods of using the same |
| WO2014116573A1 (en) | 2013-01-22 | 2014-07-31 | Celgene Corporation | Processes for the preparation of isotopologues of 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable salts thereof |
| AU2014236597A1 (en) | 2013-03-14 | 2015-09-24 | Deuterx, Llc | 3-(substituted-4-oxo-quinazolin-3(4H)-yl)-3-deutero-piperidine-2,6-dione derivatives |
| US20150258082A1 (en) * | 2014-03-14 | 2015-09-17 | Francesco Parlati | Combination therapy with glutaminase inhibitors |
| BR112016029041A8 (en) | 2014-06-13 | 2021-07-20 | Calithera Biosciences Inc | use of a glutaminase inhibitor, pharmaceutical composition and pharmaceutical kit |
| EP3160486B1 (en) | 2014-06-27 | 2020-11-18 | Celgene Corporation | Compositions and methods for inducing conformational changes in cereblon other e3 ubiquitin ligases |
| WO2016022969A1 (en) | 2014-08-07 | 2016-02-11 | Calithera Biosciences, Inc. | Crystal forms of glutaminase inhibitors |
| KR20170132333A (en) | 2015-04-06 | 2017-12-01 | 칼리테라 바이오사이언시즈, 인코포레이티드 | Treatment of lung cancer with glutaminase inhibitor |
| EP3304076A4 (en) * | 2015-06-02 | 2018-12-19 | Celgene Corporation | Methods for determining drug efficacy for treatment of cancer using ratios of cereblon associated proteins |
| AU2016288246A1 (en) | 2015-07-02 | 2018-02-01 | Celgene Corporation | Combination therapy for treatment of hematological cancers and solid tumors |
| US9809603B1 (en) | 2015-08-18 | 2017-11-07 | Deuterx, Llc | Deuterium-enriched isoindolinonyl-piperidinonyl conjugates and oxoquinazolin-3(4H)-yl-piperidinonyl conjugates and methods of treating medical disorders using same |
| JP6971239B2 (en) | 2015-10-05 | 2021-11-24 | キャリセラ バイオサイエンシーズ， インコーポレイテッド | Combination therapy with glutaminase inhibitor and immunooncology drug |
| US10830762B2 (en) * | 2015-12-28 | 2020-11-10 | Celgene Corporation | Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases |
| EP3503893A4 (en) | 2016-08-25 | 2020-04-29 | Calithera Biosciences, Inc. | Combination therapy with glutaminase inhibitors |
| CN110139649A (en) | 2016-08-25 | 2019-08-16 | 卡利泰拉生物科技公司 | With the combination treatment of glutamine enzyme inhibitor |
| RU2655625C1 (en) * | 2017-02-14 | 2018-05-29 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Саратовский государственный аграрный университет имени Н.И. Вавилова" | Method for treating breast cancer in cats |
| EP3648740A1 (en) * | 2017-07-07 | 2020-05-13 | EpicentRx, Inc. | Compositions for parenteral administration of therapeutic agents |
| AR116109A1 (en) | 2018-07-10 | 2021-03-31 | Novartis Ag | DERIVATIVES OF 3- (5-AMINO-1-OXOISOINDOLIN-2-IL) PIPERIDINE-2,6-DIONA AND USES OF THE SAME |
| PE20210405A1 (en) * | 2018-07-10 | 2021-03-02 | Novartis Ag | DERIVATIVES OF 3- (5-HYDROXY-1-OXOISOINDOLIN-2-IL) PIPERIDINE-2,6-DIONA AND ITS USE IN THE TREATMENT OF PROTEIN-DEPENDENT DISEASES WITH ZINC 2 FAMILY OF THE IKAROS FAMILY (IKZF2) |
| US11319330B2 (en) | 2018-09-07 | 2022-05-03 | Medshine Discovery Inc. | Tricyclic furan-substituted piperidinedione compound |
| EP4043455A4 (en) * | 2019-09-12 | 2023-09-20 | Medshine Discovery Inc. | Bicyclic compound that acts as crbn protein regulator |
| US20230158152A1 (en) * | 2020-03-17 | 2023-05-25 | Medshine Discovery Inc. | Proteolysis regulator and method for using same |
| US20230172923A1 (en) * | 2020-04-30 | 2023-06-08 | Bristol-Myers Squibb Company | Methods of treating cytokine-related adverse events |
| CA3182867A1 (en) * | 2020-06-25 | 2021-12-30 | Aarif Ahsan | Methods for treating cancer with combination therapies |
| CN115724775A (en) * | 2022-11-22 | 2023-03-03 | 天津大学 | Belinostat pharmaceutical co-crystal as well as preparation method and application thereof |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| US5391485A (en) | 1985-08-06 | 1995-02-21 | Immunex Corporation | DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues |
| US4810643A (en) | 1985-08-23 | 1989-03-07 | Kirin- Amgen Inc. | Production of pluripotent granulocyte colony-stimulating factor |
| JPS63500636A (en) | 1985-08-23 | 1988-03-10 | 麒麟麦酒株式会社 | DNA encoding multipotent granulocyte colony stimulating factor |
| US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| IT1229203B (en) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | USE OF 5 METHYLTHETRAHYDROPHOLIC ACID, 5 FORMYLTHETRAHYDROPHOLIC ACID AND THEIR PHARMACEUTICALLY ACCEPTABLE SALTS FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS IN THE FORM OF CONTROLLED RELEASE ACTIVE IN THE THERAPY OF MENTAL AND ORGANIC DISORDERS. |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| KR0166088B1 (en) | 1990-01-23 | 1999-01-15 | . | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| US5360352A (en) | 1992-12-24 | 1994-11-01 | The Whitaker Corporation | Wire retainer for current mode coupler |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| IT1270594B (en) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | CONTROLLED RELEASE PHARMACEUTICAL COMPOSITION OF LIQUID SUSPENSION MOGUISTEIN |
| US5635517B1 (en) | 1996-07-24 | 1999-06-29 | Celgene Corp | Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines |
| US6281230B1 (en) | 1996-07-24 | 2001-08-28 | Celgene Corporation | Isoindolines, method of use, and pharmaceutical compositions |
| HU228769B1 (en) | 1996-07-24 | 2013-05-28 | Celgene Corp | Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha |
| US7629360B2 (en) | 1999-05-07 | 2009-12-08 | Celgene Corporation | Methods for the treatment of cachexia and graft v. host disease |
| PT1353672E (en) | 2000-11-30 | 2008-01-11 | Childrens Medical Center | Synthesis of 4-amino-thalidomide enantiomers |
| US7091353B2 (en) | 2000-12-27 | 2006-08-15 | Celgene Corporation | Isoindole-imide compounds, compositions, and uses thereof |
| US7968569B2 (en) | 2002-05-17 | 2011-06-28 | Celgene Corporation | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
| DE60331537D1 (en) * | 2002-05-17 | 2010-04-15 | Celgene Corp | COMBINATIONS FOR THE TREATMENT OF MULTIPLE MYELOMA |
| HUE035389T2 (en) * | 2006-09-26 | 2018-05-02 | Celgene Corp | 5-substituted quinazolinone derivatives as anti-cancer agents |
| RU2567753C2 (en) * | 2010-02-11 | 2015-11-10 | Селджин Корпорейшн | Arylmethoxy isoindolin derivative, compositions including thereof and methods of their application |
| WO2012012448A1 (en) * | 2010-07-19 | 2012-01-26 | Bipar Sciences, Inc. | Methods of treating breast cancer using 4-iodo-3-nitrobenzamide in combination with anti-tumor agents |
| JP2013537045A (en) * | 2010-09-15 | 2013-09-30 | アルマック ダイアグノスティックス リミテッド | Molecular diagnostic tests for cancer |
| US20140148473A1 (en) | 2011-03-11 | 2014-05-29 | Celgene Corporation | Use of 3-(5-amino-2-methyl-4-oxoquinazolin-3(4h)-yl)piperidine-2,6-dione in treatment of immune-related and inflammatory diseases |
| NO2683708T3 (en) | 2011-03-11 | 2018-03-31 | ||
| CA2834535A1 (en) | 2011-04-29 | 2012-11-01 | Celgene Corporation | Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor |
| ES2872967T3 (en) * | 2012-06-29 | 2021-11-03 | Celgene Corp | Methods to determine drug efficacy using IKZF3 (AIOLOS) |
| ES2881220T3 (en) | 2012-08-09 | 2021-11-29 | Celgene Corp | Cancer treatment methods using 3- (4 - ((4- (morpholinomethyl) benzyl) oxy) -1-oxoisoindolin-2-yl) piperidine-2,6-dione |
-
2013
- 2013-09-09 BR BR112015005243A patent/BR112015005243A2/en not_active IP Right Cessation
- 2013-09-09 KR KR1020157009163A patent/KR20150054962A/en not_active Application Discontinuation
- 2013-09-09 US US14/426,114 patent/US9694015B2/en active Active
- 2013-09-09 CA CA2884103A patent/CA2884103A1/en active Pending
- 2013-09-09 CN CN201380058688.2A patent/CN104797256A/en active Pending
- 2013-09-09 AU AU2013312188A patent/AU2013312188A1/en not_active Withdrawn
- 2013-09-09 JP JP2015531278A patent/JP6306592B2/en active Active
- 2013-09-09 MX MX2015003114A patent/MX2015003114A/en unknown
- 2013-09-09 EA EA201590535A patent/EA201590535A1/en unknown
- 2013-09-09 SG SG11201501653RA patent/SG11201501653RA/en unknown
- 2013-09-09 EP EP13762713.9A patent/EP2892537A1/en not_active Withdrawn
- 2013-09-09 WO PCT/US2013/058744 patent/WO2014039960A1/en active Application Filing
-
2015
- 2015-03-04 IL IL237558A patent/IL237558A0/en unknown
- 2015-03-09 PH PH12015500513A patent/PH12015500513A1/en unknown
- 2015-03-09 NI NI201500032A patent/NI201500032A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US9694015B2 (en) | 2017-07-04 |
| IL237558A0 (en) | 2015-04-30 |
| CA2884103A1 (en) | 2014-03-13 |
| KR20150054962A (en) | 2015-05-20 |
| WO2014039960A1 (en) | 2014-03-13 |
| EA201590535A1 (en) | 2015-07-30 |
| NI201500032A (en) | 2015-09-21 |
| CN104797256A (en) | 2015-07-22 |
| EP2892537A1 (en) | 2015-07-15 |
| PH12015500513A1 (en) | 2015-04-27 |
| MX2015003114A (en) | 2015-07-06 |
| US20150224104A1 (en) | 2015-08-13 |
| JP6306592B2 (en) | 2018-04-04 |
| AU2013312188A1 (en) | 2015-03-26 |
| JP2015527404A (en) | 2015-09-17 |
| BR112015005243A2 (en) | 2017-07-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL288181A (en) | Methods of treating cancer | |
| IL237558A0 (en) | Methods for the treatment of locally advanced breast cancer | |
| HK1254859A1 (en) | Methods for the treatment of breast cancer | |
| HK1201413A1 (en) | Treatment of breast cancer | |
| IL238116B (en) | Process for making compounds for use in the treatment of cancer | |
| HK1214128A1 (en) | Treatment of cancer | |
| HK1205254A1 (en) | Methods of treatment of cancer | |
| IL254964A0 (en) | Method for treating breast cancer | |
| HK1206642A1 (en) | Method of adjuvant cancer treatment | |
| GB201217892D0 (en) | Treatment of cancer | |
| HK1204956A1 (en) | Treatment of cancer | |
| EP2888594A4 (en) | Method for determining breast cancer treatment | |
| PL2855475T3 (en) | Alpha-carbolines for the treatment of cancer | |
| EP2849786A4 (en) | Methods for treatment of gastric cancer | |
| IL237229A0 (en) | Methods for treatment of cancer using lipoplatin | |
| GB201217890D0 (en) | Treatment of cancer | |
| GB201208296D0 (en) | Treatment of cancer |